AMPK-independent down-regulation of cFLIP and sensitization to TRAIL-induced apoptosis by AMPK activators

Biochemical Pharmacology

Volumn 79, Issue 6, 2010, Pages 853-863

  García García, Celina ^a   Fumarola, Claudia ^a,b   Navaratnam, Naveenan ^c   Carling, David ^c   López Rivas, Abelardo ^a  

^a CSIC   (Spain)

^b UNIVERSITY OF PARMA   (Italy)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

AMPK; Apoptosis; FLIP; TRAIL; Tumor

Indexed keywords

6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; ANTINEOPLASTIC AGENT; ENZYME ACTIVATOR; FLICE INHIBITORY PROTEIN; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ALPHA1; NUCLEOTIDE DERIVATIVE; PHENFORMIN; RIBONUCLEOTIDE; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; DOWN REGULATION; DRUG MECHANISM; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

ADENYLATE KINASE; AMP-ACTIVATED PROTEIN KINASES; APOPTOSIS; BREAST NEOPLASMS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL LINE, TUMOR; DOWN-REGULATION; ENZYME ACTIVATORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; PROTEIN SUBUNITS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 74149083791     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.10.022     Document Type: Article

References (51)

1. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 7 (2008) 1001-1012
2. Keane M.M., Ettenberg S.A., Nau M.M., Russell E.K., and Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 59 (1999) 734-741
3. Wang S., and El-Deiry W.S. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 22 (2003) 8628-8633
4. Chinnaiyan A.M., Prasad U., Shankar S., Hamstra D.A., Shanaiah M., Chenevert T.L., et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci USA 97 (2000) 1754-1759
5. Frew A.J., Lindemann R.K., Martin B.P., Clarke C.J., Sharkey J., Anthony D.A., et al. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci USA 105 (2008) 11317-11322
6. Palacios C., Yerbes R., and Lopez-Rivas A. Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells. Cancer Res 66 (2006) 8858-8869
7. Sprick M.R., Weigand M.A., Rieser E., Rauch C.T., Juo P., Blenis J., et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12 (2000) 599-609
8. Deng Y., Lin Y., and Wu X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. Genes Dev 16 (2002) 33-45
9. Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V., et al. Inhibition of death receptor signals by cellular FLIP. Nature 388 (1997) 190-195
10. Yeh W.C., Itie A., Elia A.J., Ng M., Shu H.B., Wakeham A., et al. Requirement for Casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development. Immunity 12 (2000) 633-642
11. Krueger A., Schmitz I., Baumann S., Krammer P.H., and Kirchhoff S. Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol Chem 276 (2001) 20633-20640
12. Sharp D.A., Lawrence D.A., and Ashkenazi A. Selective knockdown of the long variant of cellular FLICE inhibitory protein augments death receptor-mediated caspase-8 activation and apoptosis. J Biol Chem 280 (2005) 19401-19409
13. Hardie D.G. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8 (2007) 774-785
14. Carling D. The AMP-activated protein kinase cascade-a unifying system for energy control. Trends Biochem Sci 29 (2004) 18-24
15. Momcilovic M., Hong S.P., and Carlson M. Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMP-activated protein kinase in vitro. J Biol Chem 281 (2006) 25336-25343
16. Witters L.A., Kemp B.E., and Means A.R. Chutes and Ladders: the search for protein kinases that act on AMPK. Trends Biochem Sci 31 (2006) 13-16
17. Sanders M.J., Grondin P.O., Hegarty B.D., Snowden M.A., and Carling D. Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. Biochem J 403 (2007) 139-148
18. Cool B., Zinker B., Chiou W., Kifle L., Cao N., Perham M., et al. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab 3 (2006) 403-416
19. Goransson O., McBride A., Hawley S.A., Ross F.A., Shpiro N., Foretz M., et al. Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J Biol Chem 282 (2007) 32549-32560
20. Sanders M.J., Ali Z.S., Hegarty B.D., Heath R., Snowden M.A., and Carling D. Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family. J Biol Chem 282 (2007) 32539-32548
21. Su R.Y., Chao Y., Chen T.Y., Huang D.Y., and Lin W.W. 5-Aminoimidazole-4-carboxamide riboside sensitizes TRAIL- and TNFα-induced cytotoxicity in colon cancer cells through AMP-activated protein kinase signaling. Mol Cancer Ther 6 (2007) 1562-1571
22. Ido Y., Carling D., and Ruderman N. Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: inhibition by the AMP-activated protein kinase activation. Diabetes 51 (2002) 159-167
23. Russell III R.R., Li J., Coven D.L., Pypaert M., Zechner C., Palmeri M., et al. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 114 (2004) 495-503
24. Guenther G.G., Peralta E.R., Rosales K.R., Wong S.Y., Siskind L.J., and Edinger A.L. Ceramide starves cells to death by downregulating nutrient transporter proteins. Proc Natl Acad Sci USA 105 (2008) 17402-17407
25. Harper N., Farrow S.N., Kaptein A., Cohen G.M., and MacFarlane M. Modulation of tumor necrosis factor apoptosis-inducing ligand-induced NF-kappa B activation by inhibition of apical caspases. J Biol Chem 276 (2001) 34743-34752
26. Ruiz-Ruiz C., and Lopez-Rivas A. Mitochondria-dependent and -independent mechanisms in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis are both regulated by interferon-gamma in human breast tumour cells. Biochem J 365 (2002) 825-832
27. Munoz-Pinedo C., Ruiz-Ruiz C., Ruiz de Almodovar C., Palacios C., and Lopez-Rivas A. Inhibition of glucose metabolism sensitizes tumor cells to death receptor-triggered apoptosis through enhancement of death-inducing signaling complex formation and apical procaspase-8 processing. J Biol Chem 278 (2003) 12759-12768
28. Parker A.L., McVey J.H., Doctor J.H., Lopez-Franco O., Waddington S.N., Havenga M.J., et al. Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup D. J Virol 81 (2007) 3627-3631
29. Woods A., Cheung P.C., Smith F.C., Davison M.D., Scott J., Beri R.K., et al. Characterization of AMP-activated protein kinase beta and gamma subunits. Assembly of the heterotrimeric complex in vitro. J Biol Chem 271 (1996) 10282-10290
30. Davies S.P., Carling D., and Hardie D.G. Tissue distribution of the AMP-activated protein kinase, and lack of activation by cyclic-AMP-dependent protein kinase, studied using a specific and sensitive peptide assay. Eur J Biochem 186 (1989) 123-128
31. Nam S.Y., Jung G.A., Hur G.C., Chung H.Y., Kim W.H., Seol D.W., et al. Upregulation of FLIP(S) by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers. Cancer Sci 94 (2003) 1066-1073
32. Woods A., Azzout-Marniche D., Foretz M., Stein S.C., Lemarchand P., Ferre P., et al. Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase. Mol Cell Biol 20 (2000) 6704-6711
33. Daniel T., and Carling D. Functional analysis of mutations in the gamma 2 subunit of AMP-activated protein kinase associated with cardiac hypertrophy and Wolff-Parkinson-White syndrome. J Biol Chem 277 (2002) 51017-51024
34. Chang D.W., Xing Z., Pan Y., Algeciras-Schimnich A., Barnhart B.C., Yaish-Ohad S., et al. c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J 21 (2002) 3704-3714
35. Fukazawa T., Fujiwara T., Uno F., Teraishi F., Kadowaki Y., Itoshima T., et al. Accelerated degradation of cellular FLIP protein through the ubiquitin-proteasome pathway in p53-mediated apoptosis of human cancer cells. Oncogene 20 (2001) 5225-5231
36. Jones R.G., Plas D.R., Kubek S., Buzzai M., Mu J., Xu Y., et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18 (2005) 283-293
37. Okoshi R., Ozaki T., Yamamoto H., Ando K., Koida N., Ono S., et al. Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J Biol Chem 283 (2008) 3979-3987
38. Hallstrom T.C., Mori S., and Nevins J.R. An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell 13 (2008) 11-22
39. Fesik S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5 (2005) 876-885
40. Trauzold A., Siegmund D., Schniewind B., Sipos B., Egberts J., Zorenkov D., et al. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 25 (2006) 7434-7439
41. Held J., and Schulze-Osthoff K. Potential and caveats of TRAIL in cancer therapy. Drug Resist Updat 4 (2001) 243-252
42. Ruiz-Ruiz C., Munoz-Pinedo C., and Lopez-Rivas A. Interferon-gamma treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program. Cancer Res 60 (2000) 5673-5680
43. Guigas B., Sakamoto K., Taleux N., Reyna S.M., Musi N., Viollet B., et al. Beyond AICA riboside: in search of new specific AMP-activated protein kinase activators. IUBMB Life 61 (2009) 18-26
44. Moreno D., Knecht E., Viollet B., and Sanz P. A769662, a novel activator of AMP-activated protein kinase, inhibits non-proteolytic components of the 26S proteasome by an AMPK-independent mechanism. FEBS Lett 582 (2008) 2650-2654
45. King T.D., Song L., and Jope R.S. AMP-activated protein kinase (AMPK) activating agents cause dephosphorylation of Akt and glycogen synthase kinase-3. Biochem Pharmacol 71 (2006) 1637-1647
46. Vazquez-Martin A., Oliveras-Ferraros C., and Menendez J.A. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle 8 (2009) 88-96
47. Lopez J.M., Santidrian A.F., Campas C., and Gil J. 5-Aminoimidazole-4-carboxamide riboside induces apoptosis in Jurkat cells, but the AMP-activated protein kinase is not involved. Biochem J 370 (2003) 1027-1032
48. Cornforth A.N., Davis J.S., Khanifar E., Nastiuk K.L., and Krolewski J.J. FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells. Oncogene 27 (2008) 4422-4433
49. Nam S.Y., Amoscato A.A., and Lee Y.J. Low glucose-enhanced TRAIL cytotoxicity is mediated through the ceramide-Akt-FLIP pathway. Oncogene 21 (2002) 337-346
50. MacFarlane M., Harper N., Snowden R.T., Dyer M.J., Barnett G.A., Pringle J.H., et al. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene 21 (2002) 6809-6818
51. Jin T.G., Kurakin A., Benhaga N., Abe K., Mohseni M., Sandra F., et al. Fas-associated protein with death domain (FADD)-independent recruitment of c-FLIPL to death receptor 5. J Biol Chem 279 (2004) 55594-55601